Helicobacter pylori and the prevention of gastric cancer

Canadian Journal of Gastroenterology

Volumn 18, Issue 5, 2004, Pages 295-302

  Sullivan, Terrence ^a,b   Ashbury, Fredrick D ^b,c,d   Fallone, Carlo A ^c   Naja, Farah ^a   Schabas, Richard ^e   Hébert, Philip C ^b,f   Hunt, Richard ^g   Jones, Nicola ^b,h  

^a CANCER CARE ONTARIO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d PICEPS Consulting Inc   (Canada)

^e Schabas Associates Inc   (Canada)

^f SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^g MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

^h HOSPITAL FOR SICK CHILDREN RESEARCH INSTITUTE   (Canada)

Author keywords

Cancer prevention; Gastric cancer; Health promotion; Helicobacter pylori; Primary care; Stomach

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; CLARITHROMYCIN; METRONIDAZOLE; PROTON PUMP INHIBITOR; RANITIDINE BISMUTH CITRATE;

CANADA; CANCER PREVENTION; CANCER RESEARCH; DRUG DOSE REGIMEN; DRUG SAFETY; ERADICATION THERAPY; HEALTH CARE QUALITY; HEALTH PROMOTION; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; PATHOGENESIS; PATIENT COMPLIANCE; PATIENT EDUCATION; PATIENT MONITORING; POPULATION RISK; PRACTICE GUIDELINE; PREVALENCE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROSPECTIVE STUDY; REVIEW; SCREENING TEST; STOMACH CANCER; STOMACH CARCINOGENESIS; UREA BREATH TEST; WORKSHOP;

EID: 3042549211     PISSN: 08357900     EISSN: None     Source Type: Journal    
DOI: 10.1155/2004/315184     Document Type: Review

References (72)

1. GLOBOCAN 2000: Cancer incidence, mortality and prevalence worldwide, Version 1.0. IARC CancerBase No. 5. Lyon, IARC Press, 2001.
2. Canadian Cancer Society. (Version current at March 25, 2004).
3. Lambert R, Guilloux A, Oshima A, et al. Incidence and mortality from stomach cancer in Japan, Slovenia and the USA. Int J Cancer 2002;97:811-18.
4. Alexander HR, Kelsen DG, Tepper JC. Cancer of the stomach. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. 5th edn. Philadelphia: Lippincott-Raven, 1997:1021-54.
5. Correa P. Human gastric carcinogenesis: A multistep and multifactorial process. Cancer Research 1992;52:6735-40.
6. Correa P. Helicobacter pylori and gastric cancer: State of the art. Cancer Epidemiol Biomarkers Prev 1996;5:477-81.
7. Sepulveda A, Graham DY. Role of H pylori in gastric carcinogenesis. Gastroenterology Clin 2002;31(2):517-35.
8. Huang JQ, Sridhar S, Chen Y, Hunt RH. Meta-analysis of the relationship between Helicobacter pylori seropositivity and gastric cancer. Gastroenterology 1998;114:1169-79.
9. Huang JQ, Zheng GF, Sumanac K, Irvine JE, Hunt RH. Meta-analysis of therelationship between Cag A seropositivity and gastric cancer. Gastroenterology 2003;125:1636-44.
10. Bravo LE, van Doom LJ, Realpe JL, Correa P. Virulence-associated genotypes of Helicobacter pylori: Do they explain the African enigma? Am J Gastroenterol 2002;97:2839-42.
11. Huang JQ, Hunt RH. Review article: Helicobacter pylori and gastric cancer - the clinicians' point of view. Ailment Pharmacol Ther 2000;14(Suppl 3):48-54.
12. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Helicobacter pylori. Lyon: International Agency for Research on Cancer; 1994:177-240.
13. Malaty HM, El-Kasabany A, Graham DY, at al. Age at acquisition of Helicobacter pylori infection: A follow-up study from infancy to adulthood. The Lancet 2002;359:931-35.
14. Malaty HM, Graham DY, Klein PD, Evans DF, Adam E, Evans DJ Jr. Transmission of Helicobacter pylori infection: Studies in families of healthy individuals. Scand J Gastroenterol 1991;9:927-32.
15. Bamford KB, Bickley J, Collins JS, et al. Helicobacter pylori: Comparison of DNA fingerprints evidence for intrafamilial infection. Gut 1993;34:1348-50.
16. Drumm B, Perez-Perez GI, Blaser MJ, Sherman PM. Intrafamilial clustering of Helicobacter pylori infection. N Engl J Med 1990;322:359-63.
17. Covacci A, Telford JL, Del Guidice G, et al. Helicobacter pylori virulence and genetic geography. Science 1999;284:1328-33.
18. Veldhuyzen van Zanten SJO, Pollak PT, Best LM, et al. Increasing prevalence of Helicobacter pylori infection with age: Continuous risk of infection in adults rather than cohort effect. J Infect Dis 1994;169:434-7.
19. Bernstein CN, McKeown I, Embil JM, et al. Seroprevalence of Helicobacter pylori, incidence of gastric cancer and peptic ulcer-associated hospitalizations in a Canadian Indian population. Dig Dis Sci 1999;44:668-74.
20. Sinha SK, Martin B, Sargent M, et al. Age of acquisition of Helicobacter pylori in a pediatric Canadian First Nations population. Helicobacter 2002;7:76-85.
21. Thomson AB, Barkun AN, Armstrong D, et al. The prevalence of clinically significant endoscopic findings in primary care patients with uninvestigated dyspepsia: the Canadian Adult Dyspepsia Empiric Treatment - Prompt Endoscopy (CADET-PE) study. Aliment Pharmacol Ther 2003;17:1481-91.
22. Fischbach LA, Goodman KJ, Feldman M, Aragaki C. Sources of variation of Helicobacter pylori treatment success in adults worldwide: A meta-analysis. Internat J Epidemiol 2002;31:128-39.
23. Lind T, Veldhuyzen van Zanten S, Unge P, et al. Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: The MACH 1 Study. Helicobacter 1996;138-44.
24. Hunt R, Thomson ABR, Consensus Conference Participants. Canadian Helicobacter pylori Consensus Conference. Can J Gastroenterol 1998;12:31-41.
25. Hunt RH, Fallone CA, Thomson ABR, Canadian Helicobacter Study Group. Canadian Helicobacter pylori Consensus Conference update: Infections in adults. Can J Gastroenterol 1999;13:213-7.
26. Chiba N, Marshall CP. Omeprazole once or twice daily with clarithromycin and metronidazole for Helicobacter pylori. Can J Gastroenterol 2000;14:27-31.
27. Chiba N. Omeprazole and clarithromycin with and without metronidazole for the eradication of Helicobacter pylori. Am J Gastroenterol 1996;91:2139-43.
28. Veldhuyzen van Zanten SJO, Lauritsen K, Delchier JC, et al. One-week triple therapy with esomeprazole provides effective eradication of Helicobacter pylori in duodenal ulcer disease. Aliment Pharmacol Ther 2000;14:1605-11.
29. Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med 2002;347:1175-86.
30. Hunt RH, Smaill FM, Fallone CA, Sherman PM, Veldhuyzan van Zanten SJO, Thomson ABR. Implications of antibiotic resistance in the management of Helicobacter pylori infection: Canadian Helicobacter Study Group. Can J Gastroenterol 2000;14:862-68.
31. Veldhuyzen van Zanten SJO, Hunt R, Cockeram A, et al. Adding once-daily omeprazole 20 mg to metronidazole/amoxicillin treatment for Helicobacter pylori gastritis: A randomized, double-blind trial showing the importance of metronidazole resistance. Am J Gastroenterol 1998;93:5-10.
32. Fallone CA. Epidemiology of antibiotic resistance of Helicobacter pylori in Canada. Can J Gastroenterol 2000;14:879-82.
33. Bradford-Hill A. The environment and disease: Association or causation? Proc R Soc Med 1966;58:295.
34. An international association between Helicobacter pylori infection and gastric cancer. The EUROGAST study group. Lancet 1993;341:1359-62.
35. Parsonnet J, Friedman GD, Vandersteen DP, et al. Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med 1991;325:1127-31.
36. Uemura N, Okamoto S, Yamamoto S, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001;345:784-9.
37. Rothman KJ, Greenland S. Causation and casual influence. In: Rothman KJ, Greenland S, eds. Modern Epidemiology, 2nd edn. New York: Lippincott Williams & Wilkins, 1998:7-28.
38. Shirin H, Moss SF. Helicobacter pylori induced apoptosis. Gut 1998;43:592-94.
39. Peek RM Jr, Blaser MJ. Helicobacter pylori and gastrointestinal tract cancers. Nature Rev Cancer 2002;2:28-37.
40. Peek RM Jr, Wirth HF, Moss SF, et al. Helicobacter pylori alters gastric epithelial cell cycle events and gastrin secretion in Mongolian gerbils. Gastroenterology 2000; 118:48-59.
41. Azuma T, Ito S, Sato F, et al. The role of the HLA-DQA1 gene in resistance to atrophic gastritis and gastric adenocarcinoma induced by Helicobacter pylori infection. Cancer 1998;82:1013-8.
42. Sakai T, Aoyama N, Satonaka K, et al. HLA-DQB1 locus and the development of atrophic gastritis with Helicobacter pylori infection. J Gastroenterol 1999;34(Suppl 11):24-7.
43. El-Omar EM, Carrington M, Chow WH, et al. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 2000;404:398-402.
44. Machado JC, Pharoah P, Sousa S, et al. Interleukin-1B and interleukin-1RN polymorphism are associated with increased risk of gastric carcinoma. Gastroenterology 2001;121:823-9.
45. El-Omar EM. The importance of interleukin-1 [beta] in Helicobacter pylori-associated disease. Gut 2001;48:743-7.
46. Imrie C, Rowland M, Bourke B, Drumm B. Is Helicobacter pylori infection in childhood a risk factor for gastric cancer? Pediatrics 2001;107:373-80.
47. Fallone CA, Barkun AN, Halwani F. Does Helicobacter pylori eradication prevent gastric cancer? DigLiver Dis 2001;33: 803-4.
48. Laheji RJ, Rossum LG, Jansen JB, Straatman H, Berbeek AL. Evaluation of treatment regimens to cure Helicobacter pylori infection - a meta-analysis. Ailment Pharmacol Ther 1999;13:857-64.
49. Hunt RH, Fallone CA, Thomson ABR, Canadian Helicobacter Study Group. Canadian Helicobacter pylori Consensus Conference update: Infections in adults. Can J Gastroenterol 1999;13:213-7.
50. Sung JJY, Lin SR, Ching JYL, et al. Atrophy and intestinal metaplasia one year after cure of H pylori infection: A prospective randomized Study. Gastroenterology 2000;119:7-14.
51. Uemura N, Mukai T, Okamoto S, et al. Effect of Helicobacter pylori eradication on subsequent development of cancer after endoscopic resection of early gastric cancer. Cancer Epidemiol Biomarkers Prev 1997;6:639-42.
52. Fallone CA, Barkun AN, Friedman G, et al. Is Helicobacter pylori eradication associated with gastro-esophageal reflux disease? Am J Gastroenterol 2000;95:914-20.
53. Moayyedi P, Bardhan C, Young L, Dixon MF, Brown L, Axon AT. Helicobacter pylori eradication does not exacerbate reflux symptoms in gastroesophageal reflux disease. Gastroenterology 2001;121:1120-6.
54. Chiba N, van Zanten SJV, Sinclair P, Ferguson RA, Escobedo S, Grace E. Treating Helicobacter pylori infection in primary care patients with uninvestigated dyspepsia: The Canadian adult dyspepsia empiric treatment-Helicobacter Pylori positive (CADET-Hp) randomized controlled trial. BMJ 2002;324:1-7.
55. Wildner-Christensen M, Hansen JM, Schaffalitzky de Muckadell OB. Rates of dyspepsia one year after Helicobacter pylori screening and eradication in a Danish population. Gastroenterology 2003;125:372-9.
56. Moayyedi P, Feltbower R, Brown J, et al. Effect of population screening and treatment for Helicobacter pylori on dyspepsia and quality of life in the community: A randomized controlled trial. Lancet 2000;355:1665-9.
57. Schlemper RJ, van der Werf SD, Biemond I, Lamers CB. Seroepidemiology of gastritis in Japanese and Dutch male employees with and without ulcer disease. Eur J Gastroenterol Hepatol 1996;8:33-9.
58. Feldman RA. Epidemiologic observations and open questions about disease and infection caused by Helicobacter pylori. In: Achtman M, Suerbaum S, eds. Helicobacter pylori: Molecular and Cellular Biology. Wymondham, United Kingdom: Horizon Scientific Press, 2001:29-51.
59. Marshall BJ, Goodwin CS, Warren JR, et al. Prospective double-blind trial of duodenal ulcer relapse after eradication of Campylobacter pylori. Lancet 1988;2:1437-42.
60. Hunt RH, Fallone CA, Veldhuyzan van Zanten SJO, Sherman P, Smail F, Thomson ABR. Risks and benefits of Helicobacter pylori eradication - current status. Can J Gastroenterol 2002;16:57-62.
61. Moayyedi P, Soo S, Deeks J, et al. Systematic review and economic evaluation of Helicobacter pylori eradication for nonulcer dyspepsia. BMJ 2000;321:659-64.
62. McColl K, Murray L, El-Omar E, et al. Symptomatic benefit from eradicating Helicobacter pylori infection in patients with nonulcer dyspepsia. N Engl J Med 1998;339:1869-74.
63. Parsonnet J, Harris RA, Hack HM, Owens DK. Modeling cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer: A mandate for clinical trials. Lancet 1996;348:150-4.
64. Roper W, Thacker S. Doing good before there is harm. In: Warren K, Mosteller F, eds. Doing More Good than Harm: The Evaluation of Health Care Interventions. New York; Annals of NY Academy of Sciences, 1993:33-40.
65. Sackett D, Strauss S, Richardson W, Rosenberg W, Haynes RB. Evidence-based Medicine: How to Practice & How to Teach EBM, 2nd edn. London: Churchill Livingstone, 2000:7-8,105ff.
66. Brody B. Ethical Issues in Drug Testing, Approval, and Pricing: The Clot-Dissolving Drugs. New York: OUP, 1995:170-3.
67. Hohenberger P, Gretshel S. Gastric cancer. Lancet 2003;362:305-15.
68. Hébert PC. Doing Right: A Practical Guide to Ethics for Physicians and Medical Trainees. Toronto: OUP, 1996:15.
69. Pfeiffer N. Informed consent in medical research: The consumers' view. In: Doyal L, Tobias J, eds. Informed Consent in Medical Research. London: BMJ Books, 2001:283-90.
70. Phillips P. Mixed response to new PSA screening study. JAMA 1998;280:8-9.
71. Lessard v Labrie, et al. In: Gouvain H, Rochette L. Court of Appeal confirms the jurisdiction of the Discipline Committee of the CHUQ. (Version current at March 30, 2004).
72. Sy R, Lee S, Veldhuyzen van Zanten SJO. Dramatic increase in the use of Helicobacter pylori (HP) serology across Canada despite lack of proof of efficacy of a noninvasive test and treat strategy. Can J Gastroenterol 1999;13(Suppl B):152B.